Completion and correction: Interim report Q3 2020 DanCann Pharma A/S (publ)
Completion of summary for published press release.Correction: Equtiy ratio for the period 1 July – 30 September 2020 is 0.77. It was recorded as -0.77 in the published interim report.Financial overview 1 July – 30 September 2020: · Net sales amounted to KDKK 0 (0) · The operating loss was KDKK 2,298 (298) · The loss per share was DKK 0.16 (2,980) · The equity ratio was 0.77 (-4.98) Highlights during the period: · On 6 July 2020 Jeppe Krog Rasmussen, CEO and Founder, entered the Board of Directors of DanCann Pharma. · On 22 September 2020 John Morell Frellsen